Embed Notice

HTML Code

<blockquote style="position: relative; padding-left: 55px;"><section><a href="https://mastodon.social/users/arstechnica/statuses/113510731526283516">Ars Technica (arstechnica@mastodon.social)'s status on Wednesday, 20-Nov-2024 02:18:54 JST</a><a href="https://mastodon.social/@arstechnica" title="arstechnica@mastodon.social"><img src="https://gnusocial.jp/avatar/115243-48-20230427195124.webp" width="48" height="48" alt="Ars Technica" style="position: absolute; left: 0; top: 0;">Ars Technica</a></section><article><p>Novo Nordisk sells hit weight-loss drug in China—at fraction of US price<br>As US struggles to afford GLP-1 drugs, the rest of the world sees much lower prices.<br><a href="https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/?utm_brand=arstechnica&amp;utm_social-type=owned&amp;utm_source=mastodon&amp;utm_medium=social" rel="nofollow noreferrer">https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/?utm_brand=arstechnica&amp;utm_social-type=owned&amp;utm_source=mastodon&amp;utm_medium=social</a></p></article><footer><a rel="bookmark" href="https://gnusocial.jp/conversation/4029909#notice-7874893">In conversation</a><time datetime="2024-11-20T02:18:54+09:00" title="Wednesday, 20-Nov-2024 02:18:54 JST">about 2 days ago</time> <span>from <span><a href="https://mastodon.social/@arstechnica/113510731526283516" rel="external" title="Sent from mastodon.social via ActivityPub">mastodon.social</a></span></span><a href="https://mastodon.social/@arstechnica/113510731526283516">permalink</a><h4>Attachments</h4><ol><li><label><a rel="external" href="https://gnusocial.jp/attachment/3523779">Untitled attachment</a></label><br><a href="https://files.mastodon.social/media_attachments/files/113/510/731/469/429/131/original/b29e3f367aeeb468.jpeg" rel="external">https://files.mastodon.social/media_attachments/files/113/510/731/469/429/131/original/b29e3f367aeeb468.jpeg</a></li><li><article><header><div>Domain not in remote thumbnail source whitelist: cdn.arstechnica.net</div><h5><a href="https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/?utm_brand=arstechnica&amp;utm_social-type=owned&amp;utm_source=mastodon&amp;utm_medium=social">Novo Nordisk sells hit weight-loss drug in China—at fraction of US price</a></h5><div></div></header><div>As US struggles to afford GLP-1 drugs, the rest of the world sees much lower prices.</div><footer></footer></article></li></ol></footer></blockquote>

Corresponding Notice

Embed this notice
Ars Technica (arstechnica@mastodon.social)'s status on Wednesday, 20-Nov-2024 02:18:54 JST Ars Technica
Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
As US struggles to afford GLP-1 drugs, the rest of the world sees much lower prices.
https://arstechnica.com/health/2024/11/novo-nordisk-sells-hit-weight-loss-drug-in-china-at-fraction-of-us-price/?utm_brand=arstechnica&utm_social-type=owned&utm_source=mastodon&utm_medium=social
In conversationabout 2 days ago from mastodon.socialpermalink
Attachments
1. Untitled attachment
  https://files.mastodon.social/media_attachments/files/113/510/731/469/429/131/original/b29e3f367aeeb468.jpeg
2. Domain not in remote thumbnail source whitelist: cdn.arstechnica.net
  Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
  As US struggles to afford GLP-1 drugs, the rest of the world sees much lower prices.

Public

Embed Notice

HTML Code

Corresponding Notice